Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 19, 2021

Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

Author(s)Michael E. Thase, MD, Gustavo Alva, MD, DFAPA, Theresa Cerulli, MD

Michael E. Thase, MD, presents the case of a 47-year-old man with treatment resistant bipolar depression.

Episodes in this series

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 3 Clinical Impressions From Patient Case #1

EP. 3 Clinical Impressions From Patient Case #1

EP. 4 Diagnosis of Bipolar Disorder

EP. 4 Diagnosis of Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 8 Role of Telemedicine in Bipolar Disorder

EP. 8 Role of Telemedicine in Bipolar Disorder

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

smoking cessation

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

ByDavid N. Osser, MD

August 18th 2026

bipolar

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

categories

Categories vs Dimensions: Wave or Particle?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

July 29th 2026

bipolar woman

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

nibelheim/Adobe Stock

Brain Trust: Addiction Pharmacotherapy in Bipolar Disorder, Rethinking Comorbidity With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 1st 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

Why Cultural Context Matters in Psychiatric Assessment

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder